EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antitumor Activity of the Ethanolic Extract from Syzygium aromaticum in Colorectal Cancer Xenograft Mice

Thunyatorn Yimsoo iD, Weerakit Taychaworaditsakul iD, Hathaichanok Chuntakaruk, Worapapar Treesuppharat, Sumet Kongkiatpaiboon iD, Apipu Ariyachayut, Sunee Chansakaow, Teera Chewonarin iD, Parirat Khonsung, Seewaboon Sireeratawong

Pharmaceutics · 07.01.2026 · 18 (1) · 79

DOI: 10.3390/pharmaceutics18010079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.01.2026. Verfasst von Thunyatorn Yimsoo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of medicine, Chaing Mai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, and the development of effective therapies with improved safety profiles is urgently needed. The hydrodistillation residue extract of Syzygium aromaticum (SA) is rich in phenolic compounds, including ellagic acid and gallic acid, which are known for their antioxidant and anticancer properties. This study aimed to evaluate the anticancer efficacy, safety, and metabolic effects of SA extract in CRC models.

Methods

The anticancer activity of SA was investigated using in vitro and in vivo approaches. Human colorectal cancer HCT116-Red-FLuc cells were used to assess cytotoxicity, selectivity, and dose- and time-dependent effects. In vivo efficacy was evaluated in a CRC xenograft mouse model using tumor volume measurement, micro-ultrasound imaging, and bioluminescence analysis. Hematological and blood biochemical parameters were analyzed to assess systemic safety. Untargeted metabolomic profiling was performed to explore metabolic alterations associated with SA treatment.

Results

SA inhibited HCT116-Red-FLuc cell proliferation in a dose- and time-dependent manner and demonstrated selective cytotoxicity toward cancer cells, with a selectivity index of 4.41 at 24 h, although selectivity declined with prolonged exposure. In xenograft mice, SA significantly suppressed tumor growth and reduced metastatic incidence. The 500 mg/kg dose (SA500) showed the greatest antitumor efficacy while maintaining normal hematological and biochemical profiles, indicating a favorable safety margin compared with 5-fluorouracil (5FU). The 1000 mg/kg dose (SA1000) induced marked suppression of Ki-67, Bcl-2, and CD31 expression and enhanced apoptosis. Metabolomic analysis identified 44 differential metabolites related to fatty acid, amino acid, and nucleotide metabolism.

Conclusions

These findings suggest that SA extract exerts significant antitumor activity against CRC with improved tolerability compared with conventional chemotherapy, supporting its potential as a complementary natural therapeutic candidate.

Schlagwörter

Stichwörter der Autor:innen

Syzygium aromaticumcolorectal cancerhydrodistillation residue of clovemetabolomicxenograft mice

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Laboratory Animal Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani 12120, Thailand.
  • Thammasat University Research Unit in Mechanisms of Drug Action and Molecular Imaging, Thammasat University, Pathum Thani 12120, Thailand.
  • Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Center for Artificial Intelligence in Medicine, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • Center of Excellence in Computational Molecular Biology, Chulalongkorn University, Bangkok 10330, Thailand.

ORCID-Profile: Thunyatorn Yimsoo, Weerakit Taychaworaditsakul, Sumet Kongkiatpaiboon, Teera Chewonarin

Förderung

  • Faculty of medicine, Chaing Mai University

Zitieren

APA

Yimsoo, T., Taychaworaditsakul, W., Chuntakaruk, H., Treesuppharat, W., Kongkiatpaiboon, S., Ariyachayut, A., Chansakaow, S., Chewonarin, T., Khonsung, P., & Sireeratawong, S. (2026). Antitumor Activity of the Ethanolic Extract from Syzygium aromaticum in Colorectal Cancer Xenograft Mice. Pharmaceutics, 18(1), 79. https://doi.org/10.3390/pharmaceutics18010079

Vancouver

Yimsoo T, Taychaworaditsakul W, Chuntakaruk H, Treesuppharat W, Kongkiatpaiboon S, Ariyachayut A, et al. Antitumor Activity of the Ethanolic Extract from Syzygium aromaticum in Colorectal Cancer Xenograft Mice. Pharmaceutics. 2026;18(1):79. doi:10.3390/pharmaceutics18010079

BibTeX
@article{Yimsoo2026,
  author = {Yimsoo, Thunyatorn and Taychaworaditsakul, Weerakit and Chuntakaruk, Hathaichanok and Treesuppharat, Worapapar and Kongkiatpaiboon, Sumet and Ariyachayut, Apipu and Chansakaow, Sunee and Chewonarin, Teera and Khonsung, Parirat and Sireeratawong, Seewaboon},
  title = {Antitumor Activity of the Ethanolic Extract from Syzygium aromaticum in Colorectal Cancer Xenograft Mice},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {79},
  doi = {10.3390/pharmaceutics18010079}
}
Kostenlos starten →